Shares of Avid Bioservices (NASDAQ:CDMO) moved higher after the company reported Q2 results.
Quarterly Results
Earnings per share were up 133.33% over the past year to $0.01, which beat the estimate of ($0.06).
Revenue of $21,064,000 up by 15.02% from the same period last year, which beat the estimate of $15,490,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Dec 02, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/jok7k959
Price Action
Company's 52-week high was at $9.37
52-week low: $3.02
Price action over last quarter: Up 11.76%
Company Profile
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on development and current Good Manufacturing Practices (cGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.
https://finance.yahoo.com/news/recap-avid-bioservices-q2-earnings-211940658.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.